Ovarian Cancer

List of contributors
Preface
Foreword
Overview - The genetics of ovarian cancer	p. 3
Molecular cytogenetic studies	p. 17
Changes in gene expression	p. 25
Genetic testing of high risk women for BRCA1 and BRCA2	p. 35
Tumour suppressor genes and cellular senescence	p. 49
New insights into the role of the TP53 tumour suppressor gene	p. 67
Molecular cloning of a zinc-finger gene based on its potential relevance to ovarian cancer aetiology	p. 77
Overview - The molecular biology of ovarian cancer	p. 87
Ovarian epithelial growth regulation	p. 99
Regulation of growth of ovarian cancer cells by phospholipid growth factors	p. 109
Tumour cell-stromal interactions: proleases and protease inhibitors	p. 121
Inhibin and activin	p. 131
Factors influencing chemokine expression and host cell infiltrate	p. 139
RhG-CSF signalling	p. 149
The clinical role of nitric oxide in treatment	p. 155
Endometriosis and the relationship with ovarian cancer	p. 159
Overview - Progress in screening for ovarian cancer	p. 173
Quantifying risk of ovarian cancer using longitudinal CA125 levels	p. 187
Prognostic factors	p. 199
Cost effectiveness analysis of screening strategies	p. 217
Overview - The development of novel treatment strategies for ovarian cancer gene therapy	p. 233
Functional analysis of the BRCA1 gene product	p. 251
p53-mediated gene therapy	p. 259
Interleukin-2 and transforming growth factor beta antisense gene therapy in a preclinical model system	p. 273
In vivo efficiency of an anti-erb B2 intracellular single chain antibody in combination with cisplatin in a murine model	p. 283
Virus-directed enzyme prodrug therapy	p. 293
Overview - High-dose and intraperitoneal therapy	p. 311
High-dose chemotherapy with autologous stem cell transplantation	p. 321
The role of intraperitoneal chemotherapy	p. 333
Second-line intraperitoneal chemotherapy	p. 341
Intraperitoneal hyperthermic chemotherapy	p. 347
Overview - New drug strategies in ovarian cancer	p. 355
Strategies for new drugs and their combination	p. 363
Cytokine-drug interactions and the potential for integrated therapies	p. 373
Gemcytabine: a strategy for combination therapy	p. 385
Paclitaxel: can we afford it?	p. 395
Overview - Quality of life assessment and issues	p. 409
Pain management	p. 419
Family issues in advanced ovarian cancer	p. 427
Relationship and sexuality issues	p. 435
How to break bad news - a practical protocol for healthcare professionals	p. 445
Conclusions and Recommendations	p. 455
Index	p. 465
Table of Contents provided by Blackwell. All Rights Reserved.

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.